Search
Esperion Therapeutics Inc
ESPRAdd to Watchlist
3.180USD
0.0000.00%
Close 07-10 16:00（ET）
819.46MMarket Cap
LossP/E TTM
TradingKey Chart
Intraday
1m
30m
1h
D
W
M
D
Today
0.00%
5 Days
0.00%
1 Month
0.00%
6 Months
0.00%
Year to Date
0.00%
1 Year
0.00%
Key Figures
--Open
0.000High
0.00Volume
LossP/E TTM
30.59P/E Dynamic
--Dividend TTM
22.96%Turnover Ratio
3.180Prev. Close
0.000Low
0.00Turnover
LossP/E Static
-2.66P/B
0.00%Div Yield TTM
-1.89%ROA
4.17552wk High
1.63Volume Ratio
-51.74MNet Profit
257.40MShares
-0.0031EPS TTM
1.04Beta
--ROE
0.80752wk Low
0.31%Amplitude
56.84%Gross Margin
819.46MMarket Cap
0.31Reward/Risk
4.11%Risk Rate
Eli Lilly and Co Stock (LLY) Moved Up by 4.44% on May 1: Facts Behind the Movement
• Eli Lilly's Q1 2026 earnings surpassed expectations; revenue grew significantly. • Management raised full-year 2026 revenue and EPS guidance, signaling confidence. • FDA proposed excluding tirzepatide from compounding list, protecting market share.
TradingKeyFri, May 1
Merck & Co Inc Stock (MRK) Moved Up by 4.09% on May 1: Key Drivers Unveiled
• Merck Q1 revenue $16.29B, beating estimates. • KEYTRUDA sales rose 8%, WINREVAIR sales surged 88%. • Merck raised full-year 2026 revenue and EPS guidance.
TradingKeyFri, May 1
Amgen Inc Stock (AMGN) Opened Down by 4.69% on May 1: A Full Analysis
• Amgen beat first-quarter 2026 earnings and revenue estimates. • FDA proposed withdrawing Tavneos, impacting company outlook. • Prolia sales declined 34% due to patent expiration and competition.
TradingKeyFri, May 1
Esperion Therapeutics Inc's Score
0.00vs previous score
Forecast6.00
Financial Health8.25
Technical1.40
Valuation Dimensions9.50
Institutional Confidence5.00
Risk Assessment4.18
Media Coverage
Coverage Level
Very Low
Very High
Neutral
Analyst Rating
Financial Indicators
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
Earnings
Next reporting date
--
Reporting Period
2026Q1
Earnings / Forecast
-0.10/-0.03
Revenue / Forecast
80.10M/84.52M
Esperion Therapeutics Inc Profile
SectorPharmaceuticals
Ticker SymbolESPR
Number of employees304
CountryUnited States of America
Ownership
| Shareholders | Proportion |
|---|---|
| BlackRock Institutional Trust Company, N.A. | 6.23% |
| Wasatch Global Investors Inc | 6.13% |
| Two Seas Capital LP | 4.62% |
| Vanguard Capital Management, LLC | 4.05% |
| Shareholder Types | Proportion |
|---|---|
| Investment Advisor | 24.53% |
| Investment Advisor/Hedge Fund | 19.24% |
| Hedge Fund | 15.74% |
| Private Equity | 3.56% |
Related Instruments
+1.28%
+1.10%
+2.00%
+0.58%
+1.55%
+1.60%
+0.91%
+2.17%
+0.66%
+3.55%
+0.60%
-1.19%
+1.53%
+1.29%
-0.87%
+1.92%
+8.55%
+1.13%
+2.20%
-2.67%
FAQs
What is the current price of Esperion Therapeutics Inc (ESPR)?
The current price of Esperion Therapeutics Inc (ESPR) is 3.18.
What is the symbol of Esperion Therapeutics Inc?
The ticker symbol of Esperion Therapeutics Inc is ESPR.
What is the 52-week high of Esperion Therapeutics Inc?
The 52-week high of Esperion Therapeutics Inc is 4.17.
What is the 52-week low of Esperion Therapeutics Inc?
The 52-week low of Esperion Therapeutics Inc is 0.81.
What is the market capitalization of Esperion Therapeutics Inc?
The market capitalization of Esperion Therapeutics Inc is 819.46M.
Is Esperion Therapeutics Inc (ESPR) currently rated as Buy, Hold, or Sell?
According to analysts, Esperion Therapeutics Inc (ESPR) has an overall rating of signal_hold, with a price target of 3.16.
What is the Earnings Per Share (EPS TTM) of Esperion Therapeutics Inc (ESPR)?
The Earnings Per Share (EPS TTM) of Esperion Therapeutics Inc (ESPR) is -0.00.